Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Hecla Mining outlines medium-term silver production potential above 20 million ounces

Hecla Mining outlines medium-term silver production potential above 20 million ounces

BitgetBitget2026/11/09 18:07
  • Hecla Mining outlined silver output potential above 20 million ounces over the medium term at the RBC Precious Metals Conference.
  • Production guidance for 2026 is 15,300,000-16,100,000 ounces; medium-term growth depends on Keno Hill's ramp-up and a Midas restart.
  • Keno Hill throughput will fall to about 300 tons daily in fourth-quarter 2026, with further reductions from January 2027 pending permits and infrastructure.
  • Greens Creek's proposed pyrite concentrate circuit could add 1,000,000-1,200,000 ounces of silver annually once fully ramped up.
  • Intermittent production is targeted for late 2027; full capacity is expected in late 2028, subject to investment approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hecla Mining Company published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12